Venture Kick

Unomr develops nano-micro technology-based sensing approaches for diagnostics and drug discovery. It has a single-molecule protein modification sensor that analyzes unknown protein properties and glycosylation, supported by hardware and software for in-depth proteomics analysis using serial nanopore sensing. The technologies enable researchers across academic, biotechnology, and pharmaceutical development to advance protein characterization and product value.

Clee Medical specializes in developing innovative neuroimaging and surgical access technologies to improve precision and efficiency in neurosurgery. Their products, which include imaging and sensing systems, provide enhanced access, vision, and navigation within the brain, seamlessly integrating with existing neurosurgical equipment and current surgical routines. This enables healthcare providers to potentially enhance patient outcomes with greater precision.

Scanvio develops AI-augmented ultrasound software for enhanced endometriosis diagnosis. It empowers gynecologists with expert sonography skills, aiming to improve healthcare outcomes and surgical education.

TrueYouOmics specializes in comprehensive blood testing services, leveraging multi-omics and artificial intelligence to identify disease risks and facilitate preventive health planning. The company's innovative approach involves analyzing an individual's DNA, RNA, and protein data, then integrating these insights with medical knowledge graphs to estimate personalized disease risks. This holistic health assessment empowers individuals to proactively manage their well-being by taking preventive measures.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

HeroSupport is a medical device manufacturing company founded in 2019 and based in Veyrier, Geneva. The company specializes in creating medical immobilization devices designed to enhance patient comfort during clinical procedures. Its innovative technology transforms imaging and treatment tables into personalized support solutions, specifically catering to the needs of patients undergoing prone breast radiotherapy. This approach allows patients to benefit from tailored support, eliminating the need for them to adjust to the standard table. By improving patient comfort, HeroSupport enables healthcare providers to deliver more effective and cost-efficient cancer treatment.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

Sensawear is a medical technology company that specializes in the production of wearable, textile-integrated sensors. These sensors monitor tissue oxygenation and skin pressure in real-time, alerting users to potential pressure injuries before they occur. By providing early warnings of low-oxygenation conditions caused by high-pressure points, Sensawear's products enable users to take preventative action, such as moving or being moved, thus minimizing the risk of painful and dangerous pressure ulcers.

SightIn Health develops artificial intelligence-powered software for portable ultrasound, providing image analytics, usage guidance, and interpretation to support patient diagnosis. The platform automates quality assessment, ultrasound probe guidance, and image analysis, lowering the skill barrier required to operate ultrasound equipment and capture medical images for diagnostics and prognostics. Founded in 2021 and based in Geneva, Switzerland, SightIn Health targets healthcare providers seeking accurate, AI-assisted medical image analysis.

Developer of a metabolic health assessment platform designed to support healthcare professionals in identifying at-risk individuals before traditional diagnostics. The company uses saliva-based metabolite measurements analyzed through customized Nuclear Magnetic Resonance (NMR) spectrometry, enabling registered nutritionists and healthcare providers to assess metabolic health with minimal invasiveness, competitive cost, and early detection capabilities.

Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing, helping clients leverage these complex fields for their research.

YLAH is a technology company specializing in the development of web and mobile solutions for psychotherapists and their patients. Its core offerings include individualized therapy tools, clinical assessment platforms, and health monitoring systems, empowering therapists to efficiently scale their services using digital means.

Avelo focuses on saving lives through swift and precise infectious disease diagnoses in primary care settings. It specializes in manufacturing breath aerosol diagnostic equipment designed to enhance tuberculosis diagnosis via a non-invasive, painless breath collection device. This enables faster, accurate diagnoses using existing PCR testing infrastructure, facilitating earlier appropriate treatment and rapid patient referral.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

NexMR is a Swiss company specializing in key-in-hand solutions to enhance throughput and optimize resources for NMR-drug discovery pipelines. Its technology aims to be accessible and effective, even when addressing challenging targets.

Sensemodi develops a smart wearable that uses AI to analyze thermal, acoustic, and kinematic data to assess joint health. The device is designed to monitor knees and other joints with multiple sensor modalities, enabling users to check and track joint condition anywhere. By providing quick assessments and ongoing monitoring, Sensemodi aims to help prevent disability and reduce the socioeconomic burden of musculoskeletal disorders and support improved healthcare treatment.

Oncobit specializes in developing precise diagnostic tests and monitoring tools to enhance personalized cancer care. Its platform analyzes patient samples, offering clinicians advanced molecular insights to optimize therapy management.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Nemosia is a company focused on the development of positron emission tomography (PET) tracers aimed at diagnosing neurological disorders. Utilizing advanced technology, Nemosia creates tracers that facilitate the early detection of neurodegenerative diseases by visualizing N-methyl-D-aspartate (NMDA) receptors in the brain. This innovative approach allows for timely intervention, enabling patients to take proactive measures against neurological conditions. Through its specialized PET imaging capabilities, Nemosia contributes to improved diagnostic accuracy and better patient outcomes in the field of neurology.

ArcoScreen is a Swiss medtech company developing a microfluidic discovery platform for drug screening that targets membrane receptors, notably G-protein coupled receptors. The platform blends a lab-on-chip system with biological assays to quantify GPCR activation in primary mammalian cells, including guanosine 5'-O-(3-thiotriphosphate)-based functional readouts, and supports both ready-to-use and custom stable cell lines. This approach enables pharmaceutical researchers to investigate receptor signaling, identify drug modes of action, and perform in-vitro screenings directly on patient-derived cells. By enabling faster, more predictive screenings, ArcoScreen aims to reduce clinical attrition and accelerate the development of therapeutic candidates with improved translational relevance.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

Rea Diagnostics specializes in developing non-invasive diagnostic technology aimed at assessing the risk of preterm birth. The company's primary product is a smart pad equipped with an embedded sensor that detects proteins indicative of labor. This device incorporates a microfluidic system, a biosensing unit, and a readout system, enabling the identification and quantification of biomarkers present in vaginal fluid. The results are communicated through a mobile application, allowing healthcare professionals to make timely and informed decisions regarding the risk of premature birth. Headquartered in Lausanne, Switzerland, Rea Diagnostics addresses the need for more efficient diagnostics in the preterm birth market, ultimately supporting better outcomes for mothers and infants.

4iLabs is developing a diagnostic toolbox to support clinicians in the therapy decision-making process for patients with progressed cancer beyond the standard of care.

peakPCR develops Polymerase Chain Reaction (PCR) devices for research and private laboratories. peakPCR is a low-cost, small size device capable of performing real-time polymerase chain reaction (qPCR). PCR is a method widely used in molecular biology to duplicate DNA segments, with applications such as genotyping, mutation detection, forensics, and paternity testing. The Polymerase Chain Reaction (PCR) is a widely used molecular technique to make millions of copies of a DNA sample, with applications in a variety of fields such as medical diagnostics, biotechnology, and forensic sciences. We have analyzed the heat transfer limitations of conventional PCR machines. This has led to the design of a completely new sample holder with extremely high heating and cooling rates and a much lower sample volume, in order to cut analysis time from currently 1-2 h down to 10 minutes, and reagent consumption by 90%. Next to a first stand-alone desktop instrument, we have also developed a portable version that is battery-powered and that operates in conjunction with a smartphone. We aim to deploy these PCR devices to research and private laboratories at affordable prices.

Founded in 2020, Emovo Care is a Swiss medical device company specializing in robotic orthoses for individuals with hand motor impairments, particularly those resulting from stroke. Their flagship product is an active orthosis that enables hemiparetic stroke patients to regain hand movement at home.

Nutrix is a Swiss health-technology company focused on prevention and precision medicine. It develops a non-invasive nanosensor placed on the tooth to measure glucose levels in saliva, with data transmitted to an external application. The sensor tracks food intake and provides dietary guidance to help prevent diabetes. The company combines artificial intelligence with wearables and human care to deliver cost-effective prevention and healthcare programs, including digital coaching and telemedicine, enabling caregivers to monitor patients remotely and reduce routine doctor visits. In 2025 Nutrix expanded its offering with CortiSense, a cortisol monitoring sensor, reflecting its move into non-invasive hormonal monitoring. Based in Basel, Switzerland, Nutrix provides an integrated solution of sensors, software, and care services.

Founded in 2019, epyMetrics is a Swiss health technology company specializing in wearable solutions for continuous, non-invasive monitoring of thermoregulation. Its diagnostic wearables detect early signs of heat stress, enhancing occupational safety and reducing workplace costs.

MimiX Biotherapeutics Sàrl is a Swiss company founded in 2016 that specializes in biofabrication technology focused on tissue manufacturing for therapeutic and diagnostic applications. Based in La Tène, the company aims to revolutionize regenerative and personalized medicine through its innovative point-of-care approach. By developing ultra-fast biomanufacturing technology, MimiX Biotherapeutics seeks to create patient-specific biological tissue equivalents, facilitating tailored treatments that meet individual medical needs.

EarlySight, a Lausanne-based medical device company, develops technology to detect and treat eye diseases at an early stage. Its flagship work includes a fundus camera that images the retina with high detail by combining eye illumination with real time ocular aberration correction. The company also leverages cellular level imaging and transscleral illumination to monitor day to day treatment effects in a non invasive manner, enabling eye specialists to visualize the morphology of retinal cells. Founded in 2016, EarlySight aims to bring its imaging technology to clinics to improve early diagnosis and treatment of ocular conditions.

Selph is a medical technology company that focuses on developing a medical device that enables people to conduct a self-test for sexually transmitted diseases. It specializes in digital health, sensors, diagnostics, and medical services.

OptiChroniX is a Swiss-based digital health solutions company focused on enhancing brain health through early intervention. The company specializes in developing digital therapeutics that integrate biomedical, behavioral, computing, and engineering research. These interventions are deployed on smartphones and utilize data from wearable devices to personalize and monitor patients' health progress. OptiChroniX aims to improve clinical outcomes, quality of life, and cost-effectiveness by providing tailored coaching to enhance health literacy, medication adherence, and address modifiable risk factors associated with cognitive decline in conditions like Alzheimer’s disease and related comorbidities.

Testmate Health is a medtech startup and award-winning spin-off of the University of Geneva in Switzerland. It has developed a smartphone-compatible platform test kit capable of diagnosing diseases based on identifiable DNA or RNA sequences without the need for a laboratory, delivering results in minutes at home. The initial product is a rapid urine self-test for the four most common sexually transmitted infections, designed to be used outside clinical settings and to provide a smartphone-scanable result that supports immediate access to treatment if needed. The platform uses DNA isothermal technology to detect infectious diseases with identifiable DNA, enabling home testing without laboratory submission. Further test kits for additional diseases are in development to empower users to monitor their health from home.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

Founded in 2019, Swiss Medical Union specializes in developing and manufacturing advanced bioreactor systems for testing new medical products' interaction, efficiency, and safety using human organ and tissue models. The company offers a software suite to simulate organ activity, analyze product-organ interactions, and monitor effects in real-time. Additionally, they provide clinical testing services to hospitals, healthcare institutions, and international facilities.

Autonomyo is a Swiss company founded in 2014, based in Lausanne, that specializes in developing robotic rehabilitation solutions for individuals with neurological gait disorders. The company focuses on manufacturing a lightweight exoskeleton designed to facilitate robotically assisted gait training, which can be utilized in rehabilitation clinics as well as in home settings with remote monitoring capabilities. Autonomyo's team, comprised of engineers, developers, and healthcare professionals, is dedicated to enhancing accessibility and training intensity for people with neuromuscular and motor disorders, ultimately aiming to improve their mobility and restore their freedom of movement.

C-MedTec is a company focused on enhancing the detection and monitoring of brain concussions through innovative technology. It has developed a specialized helmet that serves as a medical imaging modality capable of measuring brain metabolism and identifying abnormal neurological behavior following a traumatic impact. This advancement addresses the significant gap in concussion diagnosis, which traditionally relies on subjective assessments by trained professionals. By providing early detection and diagnosis, C-MedTec aims to promote safer sports practices and mitigate the risk of long-term effects and chronic conditions such as Alzheimer's disease and chronic traumatic encephalopathy (CTE). Through its cutting-edge approach, the company seeks to improve health outcomes for athletes and individuals at risk of brain trauma.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.

4i Labs generates multiplexed images of biological samples for molecular view of tumours.

Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

b-rayZ is a spin-off from University Hospital Zurich that develops artificial intelligence tools for medical imaging. Its team blends radiologists, data scientists and physicians with extensive experience in imaging and radiology. The company creates predictive deep learning analytics to assess personal medical images and to support radiologists in mammography by providing real-time image quality and breast density assessments. The software enables standardized evaluation of imaging data to improve breast cancer detectability and aims to enhance diagnostic accuracy and efficiency, potentially reducing healthcare costs.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

Frater.swiss is engaged in the development and production of innovative devices and applications designed for out-of-hospital care, with a particular focus on hypothermic patients. The company creates products that assist healthcare professionals in high-stress environments, including emergency medicine, military medicine, expedition medicine, and veterinary medicine. Their offerings provide efficient measures for assessing hypothermia and stabilizing patient temperature through warm infusion, thereby enhancing the quality of medical care available in critical situations. Frater.swiss aims to empower medical personnel to effectively save lives outside traditional hospital settings.

Positrigo develops and manufactures dedicated brain positron emission tomography (PET) scanners. Its mission is to make functional brain imaging accessible for early detection of neurodegenerative diseases like Alzheimer's, Lewy body dementia, vascular dementia, and frontotemporal dementia.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

MOMM Diagnostics is a Basel-based medical technology company founded in 2018 that develops a novel in vitro diagnostic test and device for the early diagnosis of preeclampsia at the point of care, enabling earlier detection of pregnancy-related risks and improved maternal and fetal management.

DIANA develops new dosimeters for radio diagnostic applications (especially interventional radiology) based on technology developed for high energy physics experiments

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

Positrigo develops and manufactures dedicated brain positron emission tomography (PET) scanners. Its mission is to make functional brain imaging accessible for early detection of neurodegenerative diseases like Alzheimer's, Lewy body dementia, vascular dementia, and frontotemporal dementia.

DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. By leveraging machine learning, artificial intelligence, and advanced search algorithms, the platform tracks locally available caregivers and enables patients to easily find and book appointments for medical checkups at home. This innovative approach streamlines the process of accessing private medical care, allowing patients to connect with qualified doctors and physicians who offer home visit services.

Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Positrigo develops and manufactures dedicated brain positron emission tomography (PET) scanners. Its mission is to make functional brain imaging accessible for early detection of neurodegenerative diseases like Alzheimer's, Lewy body dementia, vascular dementia, and frontotemporal dementia.

IDUN Technologies designs and manufactures biosensors for wearable devices, specializing in dry conductive electrodes for bio-potential monitoring (ECG, EEG, EMG). Its innovative products enable convenient EEG monitoring suitable for consumer applications and brain-computer interfaces. Founded in 2017, the company is based in Opfikon, Switzerland.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. By leveraging machine learning, artificial intelligence, and advanced search algorithms, the platform tracks locally available caregivers and enables patients to easily find and book appointments for medical checkups at home. This innovative approach streamlines the process of accessing private medical care, allowing patients to connect with qualified doctors and physicians who offer home visit services.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Dicronis develops innovative diagnostic tools. Its flagship product, Lymphit, is a wearable device that tracks lymphatic function safely and remotely, enabling early diagnosis of secondary lymphedema, a common side effect of cancer therapies.

Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.

IDUN Technologies designs and manufactures biosensors for wearable devices, specializing in dry conductive electrodes for bio-potential monitoring (ECG, EEG, EMG). Its innovative products enable convenient EEG monitoring suitable for consumer applications and brain-computer interfaces. Founded in 2017, the company is based in Opfikon, Switzerland.

ReflectUS develops a new diagnostic device for breast cancer diagnosis based on innovations in ultrasound imaging.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Mirrakoi SA is a Swiss company specializing in the development of computer-aided design software, particularly for the medical field. Founded in 2018 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, Mirrakoi offers an innovative solution known as Rhino3DMedical. This proprietary software facilitates a streamlined workflow that allows users to view, analyze, and segment medical images, ultimately creating 3D-printable anatomical models from CT and MRI scans. The technology is designed for orthopedic surgical planning, enabling the development of patient-specific models with ease through an intuitive interface and guided workflow. Mirrakoi's focus on enhancing the design process in the medical sector positions it as a leader in augmented design technology.

Certus Molecular Diagnostics AG specializes in the development and provision of molecular rapid tests designed for the on-site detection of mycoplasma contamination in cell cultures, as well as the identification of specific genes in various microorganisms. Founded in 2007 and headquartered in Bern, Switzerland, the company aims to enhance the reliability and efficiency of microbial testing in laboratory settings. By focusing on rapid diagnostics, Certus Molecular Diagnostics addresses critical needs in research and clinical environments, offering solutions that facilitate timely decision-making and quality control in cell culture processes. The company serves both domestic and international markets, contributing to advancements in molecular diagnostics.

IDUN Technologies designs and manufactures biosensors for wearable devices, specializing in dry conductive electrodes for bio-potential monitoring (ECG, EEG, EMG). Its innovative products enable convenient EEG monitoring suitable for consumer applications and brain-computer interfaces. Founded in 2017, the company is based in Opfikon, Switzerland.

Dicronis develops innovative diagnostic tools. Its flagship product, Lymphit, is a wearable device that tracks lymphatic function safely and remotely, enabling early diagnosis of secondary lymphedema, a common side effect of cancer therapies.

MesenFlow Technologies specializes in innovative bio-imaging technology aimed at enhancing drug and cosmetic development. The company’s platform addresses critical challenges in modern drug development, including species cross-reactivity and the ethical concerns of animal testing. By utilizing proprietary protocols on primary human cells, MesenFlow enables early definition of a drug's mechanism of action and its relevance to human biology. This approach not only accelerates the pharmaceutical testing process but also extends to the cosmetics and nutraceutical sectors, allowing for the assessment of product safety and efficacy at an early stage. MesenFlow's technology is particularly beneficial for organizations requiring animal-free testing solutions, ensuring compliance with regulatory demands while prioritizing human biological impact.

ReflectUS develops a new diagnostic device for breast cancer diagnosis based on innovations in ultrasound imaging.

Komed Health is a developer of a secure messaging platform specifically designed for healthcare professionals, facilitating instant communication among medical teams. The application streamlines and organizes real-time interactions, rendering traditional in-hospital communication methods such as fixed phones, pagers, and emails increasingly obsolete. It integrates seamlessly with existing clinical systems, allowing healthcare providers to access and share critical medical information for effective decision-making at the point of care. By collaborating closely with healthcare providers, Komed Health aims to enhance its platform with advanced features tailored to the needs of modern healthcare workflows, ultimately improving care delivery through intelligent communication.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Dicronis develops innovative diagnostic tools. Its flagship product, Lymphit, is a wearable device that tracks lymphatic function safely and remotely, enabling early diagnosis of secondary lymphedema, a common side effect of cancer therapies.

Founded in Zurich, Switzerland in 2018, Sleepiz develops a non-contact multidimensional sleep monitoring device. It tracks breathing, heart rate, and body movements with medical-grade accuracy, enabling diagnosis of sleep disorders and long-term patient-centric disease management.

Komed Health is a developer of a secure messaging platform specifically designed for healthcare professionals, facilitating instant communication among medical teams. The application streamlines and organizes real-time interactions, rendering traditional in-hospital communication methods such as fixed phones, pagers, and emails increasingly obsolete. It integrates seamlessly with existing clinical systems, allowing healthcare providers to access and share critical medical information for effective decision-making at the point of care. By collaborating closely with healthcare providers, Komed Health aims to enhance its platform with advanced features tailored to the needs of modern healthcare workflows, ultimately improving care delivery through intelligent communication.

Immunas develops a point-of-care diagnostic device that within minutes will be able to determine if the source of infection is bacterial or viral. This will lead to informed antibiotic treatment decisions and reduce the number of avoidable deaths in societies due to antimicrobial resistance. Immunas is a med-tech start-up aiming to develop a rapid test allowing doctors to accurately distinguish the sources of infection. The test reduces antibiotic overuse and helps minimize antibiotic resistance. Patients receive optimal treatment faster with the test. Unlike traditional procedures that take hours to days to complete, Immunas' cutting edge chip-based technology, within minutes, will be able to accurately determine whether the cause of infection is bacterial or viral. Together with cost-effectiveness, ease-of-use, minimal invasiveness for the patient and immense potential impact on pressing public health concerns, we genuinely hope to enable smart and responsible use of antibiotics for the benefits of patients and for societies at large.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Kinastic offers digital wellness solutions for businesses. Its platform includes kinastic Club for personalized workout plans and kinastic Coach, an AI-driven virtual personal trainer creating tailored fitness programs.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

Founded in 2015 as a spin-off of ETH Zurich, Inositec is a biotechnology company that develops novel therapies for soft tissue calcification disorders. It leverages its proprietary Inositune platform to engineer small molecules with tunable properties, focusing on vascular and renal calcification disorders, including orphan indications.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Lucentix is a Swiss company that specializes in biosensor technology, enabling patients to measure precise concentrations of analytes using just a single drop of blood or saliva. The company’s innovative handheld device delivers laboratory-quality results at a low cost, enhancing accessibility and convenience for users. Its biosensors utilize a novel biochemical sensing molecule, engineered from a light-producing enzyme called luciferase, which alters the color of emitted light in response to changes in analyte concentration. In the absence of the analyte, the system emits red light, while higher concentrations produce blue light. This technology allows for rapid point-of-care testing, providing patients with timely and accurate health information. Lucentix is headquartered in Lausanne, Switzerland.

TheranOptics SARL is a Swiss company based in Neuchâtel, established in 2016. The firm specializes in the development of fiber-based sensor equipment designed for the chemical analysis of chronic wounds. Given the prevalence of chronic wounds affecting a segment of the Swiss population, TheranOptics aims to address this medical challenge through innovative technology that enhances the understanding and management of such conditions.

CellSpring is a biotechnology company based in Zurich, Switzerland, that develops 3D tissue models for biological research. Its core offering, the 3D Bloom platform, enables rapid creation of biomimetic microtissues independent of cell type, supporting in vitro studies and drug development. The platform emphasizes speed, reliability, versatility, and ease of use, improving the fabrication of 3D cell cultures for diverse experimental applications.

Founded in 2015, Axiamo specializes in developing software and manufacturing motion sensors. These sensors measure key physical performance parameters, with a focus on analyzing running scientifically. The company is based in Nidau, Switzerland.

SimplicityBio SA is a biotechnology company based in Monthey, Switzerland, founded in 2013 by Matthew Hall, Pedro Faustino, and Miguel Barreto. The company specializes in developing an artificial intelligence-based platform designed to analyze biological, clinical, and digital data streams, facilitating the extraction of knowledge and insights that expedite the development of biomarker signatures throughout various stages, from target identification to pre-clinical and clinical phases. Its services encompass biomarker discovery and ranking, signature creation, and the enhancement of existing signatures, catering to the molecular diagnostic market. In addition to its analytical capabilities, SimplicityBio also focuses on developing scientific innovations, intellectual property, and white paper technologies for its clients. As of March 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Lucentix is a Swiss company that specializes in biosensor technology, enabling patients to measure precise concentrations of analytes using just a single drop of blood or saliva. The company’s innovative handheld device delivers laboratory-quality results at a low cost, enhancing accessibility and convenience for users. Its biosensors utilize a novel biochemical sensing molecule, engineered from a light-producing enzyme called luciferase, which alters the color of emitted light in response to changes in analyte concentration. In the absence of the analyte, the system emits red light, while higher concentrations produce blue light. This technology allows for rapid point-of-care testing, providing patients with timely and accurate health information. Lucentix is headquartered in Lausanne, Switzerland.

Spectroswiss Sarl is a Swiss company established in 2014 and based in Lausanne, specializing in biological mass spectrometry. It develops advanced mass analyzers and data acquisition electronics designed to enhance research in life sciences and biotechnology. The company employs proprietary methods for processing time-domain data, enabling super-resolution signal processing in Fourier transform mass spectrometry (FTMS). This innovative approach allows clients to conduct both qualitative and quantitative analyses of proteins and metabolites, facilitating vital research and applications in the life sciences sector. Spectroswiss aims to accelerate scientific discovery by providing sophisticated tools for proteomics and metabolomics analysis.

CellSpring is a biotechnology company based in Zurich, Switzerland, that develops 3D tissue models for biological research. Its core offering, the 3D Bloom platform, enables rapid creation of biomimetic microtissues independent of cell type, supporting in vitro studies and drug development. The platform emphasizes speed, reliability, versatility, and ease of use, improving the fabrication of 3D cell cultures for diverse experimental applications.

Xsensio is a digital health company focused on revolutionizing healthcare monitoring. It specializes in developing a wearable, Lab-on-Skin© platform that continuously analyzes biochemical data from the skin's surface in real-time, offering unprecedented insights into health and wellness.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.

SimplicityBio SA is a biotechnology company based in Monthey, Switzerland, founded in 2013 by Matthew Hall, Pedro Faustino, and Miguel Barreto. The company specializes in developing an artificial intelligence-based platform designed to analyze biological, clinical, and digital data streams, facilitating the extraction of knowledge and insights that expedite the development of biomarker signatures throughout various stages, from target identification to pre-clinical and clinical phases. Its services encompass biomarker discovery and ranking, signature creation, and the enhancement of existing signatures, catering to the molecular diagnostic market. In addition to its analytical capabilities, SimplicityBio also focuses on developing scientific innovations, intellectual property, and white paper technologies for its clients. As of March 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Lunaphore develops automated tissue staining platforms for spatial biology research. Its technology uses microfluidic chips to analyze and classify tumors, enabling efficient cancer diagnostic assays.